Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $54.56 (+1.45%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 13, 2026 | David Nierengarten | Wedbush | $50.00 | -8.4% |
| Oct 29, 2024 | Liisa Bayko | Evercore ISI | $35.00 | -35.9% |
| Sep 13, 2024 | Roger Song | Jefferies | $40.00 | -26.7% |
| May 3, 2024 | Eva Fortea Verdejo | Wells Fargo | $34.00 | -37.7% |
Top Analysts Covering KNSA
KNSA vs Sector & Market
| Metric | KNSA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 9 | 8 | 18 |
| Target Upside | +17.3% | +1150.3% | +14.9% |
| P/E Ratio | 59.96 | 6.81 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $221M | $222M | $223M | 4 |
| 2026-09-30 | $233M | $236M | $237M | 2 |
| 2026-12-31 | $246M | $248M | $249M | 3 |
| 2027-03-31 | $243M | $245M | $246M | 3 |
| 2027-06-30 | $256M | $258M | $259M | 2 |
| 2027-09-30 | $263M | $265M | $267M | 2 |
| 2027-12-31 | $273M | $275M | $277M | 3 |
| 2028-12-31 | $1.24B | $1.24B | $1.24B | 7 |
| 2029-12-31 | $1.33B | $1.35B | $1.38B | 3 |
| 2030-12-31 | $1.48B | $1.51B | $1.54B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.20 | $0.25 | $0.28 | 3 |
| 2026-09-30 | $0.28 | $0.29 | $0.29 | 1 |
| 2026-12-31 | $0.36 | $0.37 | $0.37 | 1 |
| 2027-03-31 | $0.32 | $0.32 | $0.32 | 1 |
| 2027-06-30 | $0.38 | $0.38 | $0.38 | 1 |
| 2027-09-30 | $0.39 | $0.39 | $0.39 | 1 |
| 2027-12-31 | $0.42 | $0.42 | $0.42 | 1 |
| 2028-12-31 | $1.20 | $2.20 | $2.80 | 5 |
| 2029-12-31 | $2.61 | $2.67 | $2.74 | 1 |
| 2030-12-31 | $4.08 | $4.17 | $4.28 | 1 |
Frequently Asked Questions
What is the analyst consensus for KNSA?
The consensus among 9 analysts covering Kiniksa Pharmaceuticals, Ltd. (KNSA) is Buy with an average price target of $58.33.
What is the highest price target for KNSA?
The highest price target for KNSA is $50.00, set by David Nierengarten at Wedbush on 2026-01-13.
What is the lowest price target for KNSA?
The lowest price target for KNSA is $34.00, set by Eva Fortea Verdejo at Wells Fargo on 2024-05-03.
How many analysts cover KNSA?
9 analysts have issued ratings for Kiniksa Pharmaceuticals, Ltd. in the past 12 months.
Is KNSA a buy or sell right now?
Based on 9 analyst ratings, KNSA has a consensus rating of Buy (2.00/5) with a +17.3% upside to the consensus target of $58.33.
What are the earnings estimates for KNSA?
Analysts estimate KNSA will report EPS of $0.25 for the period ending 2026-06-30, with revenue estimated at $222M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.